Epoetin alfa - Alkermes/Johnson & Johnson

Drug Profile

Epoetin alfa - Alkermes/Johnson & Johnson

Alternative Names: Epoetin alfa - ProLease; Epoetin alpha - Alkermes/Johnson & Johnson; Epoetin alpha - ProLease; r-HuEPO α - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alfa - Alkermes/Johnson & Johnson; Recombinant human erythropoietin alpha - Alkermes/Johnson & Johnson

Latest Information Update: 19 Jun 2000

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kirin-Amgen
  • Developer Alkermes; Johnson & Johnson
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anaemia

Most Recent Events

  • 19 Jun 2000 Discontinued-I for Anaemia in USA (SC)
  • 25 Nov 1998 Phase-I clinical trials for Anaemia in USA (SC)
  • 09 Jul 1998 Preclinical development for Anaemia in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top